Gelsolin is an important cytoskeletal protein of platelets and studies have shown a close relationship between gelsolin and cardiovascular disease. However, the role of gelsolin in the development of coronary heart disease (CHD) is unclear. In this study, we record the distribution of gelsolin in human platelets and plasma and its association with different types of CHD. This study included 114 cases, with 33 stable angina pectoris (SAP) cases, 81 acute coronary syndrome (ACS) cases—composed of 39 unstable angina pectoris (UAP) and 42 acute myocardial infarction (AMI) cases, and 31 healthy control participants. Gelsolin concentration in platelet rich plasma (PRP) and platelet poor plasma (PPP), actin filament (F-actin) and Gc-globulin of PPP were determined by enzyme-linked immunoadsorbent assay (ELISA). The fluorescence intensity of CD62p and cytoplasmic calcium ([Ca2+]i) in human platelets measured by flow cytometry. We also used turbidimetry to detect the platelet aggregation rate (PAR). We analyzed the correlation between platelet gelsolin concentration and CD62p or plasma F-actin levels among each different patient group. Compared with the control group, the gelsolin level in PRP of UAP and AMI groups increased significantly (P<0.01), while the gelsolin level in PPP of all the three patient groups decreased markedly (P<0.01), and the CD62p, PAR, [Ca2+]i of platelets, F-actin and Gc-globulin of the UAP and AMI groups increased significantly (P<0.01). Compared with the SAP group, the gelsolin level in PRP, the PAR, [Ca2+]i of platelets and CD62p of other two groups increased significantly (P<0.01), F-actin of the AMI group increased markedly (P<0.01). Platelet cytoskeleton protein dynamics vary among the different types of CHD. Platelet gelsolin levels are markedly increased and accompanied by increased platelet activity, F-actin and [Ca2+]i of ACS patients, while gelsolin levels in PPP are markedly lower. Abnormally increased platelet gelsolin levels show high positive correlation with the level of platelet activity. Therefore, platelet gelsolin might be a novel molecular marker and/or a new potential therapeutic target of anti-platelet therapy of ACS.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution and reproduction in any medium, provided the original author(s) and source are credited.